SCHEMBL4721292

SCHEMBL4721292

CS(=O)(=O)c1ccc(-c2cc(C(F)(F)F)nc(S(C)(=O)=O)n2)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SDHB P21912 5/20 0.81
NPSR1 Q6W5P4 4/20 0.81
LMNA P02545 3/20 0.81
SMN1; SMN2 Q16637 3/20 0.81
STAT3 P40763 2/20 0.81
STAT1 P42224 2/20 0.81
RAB9A P51151 2/20 0.81
TLR9 Q9NR96 2/20 0.81
KDM4E B2RXH2 2/20 0.81
ALDH1A1 P00352 2/20 0.81
MITF O75030 1/20 0.81
TP53 P04637 3/20 0.78
HPGD P15428 3/20 0.78
KMT2A Q03164 3/20 0.78
HTT P42858 2/20 0.78
HSD17B10 Q99714 2/20 0.78
MEN1 O00255 1/20 0.78
S1PR4 O95977 1/20 0.78
POLB P06746 1/20 0.78
S1PR1 P21453 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19805665 0.90 NPSR1 (1.00) SDHBNPSR1LMNASMN1; SMN2STAT3
SCHEMBL19805673 0.90 SDHB (1.00) SDHBNPSR1LMNASMN1; SMN2STAT3
SCHEMBL29975914 0.88 NPSR1 (1.00) SDHBNPSR1LMNASMN1; SMN2STAT3
SCHEMBL28307436 0.88 NPSR1 (1.00) SDHBNPSR1LMNASMN1; SMN2STAT3
SCHEMBL19805682 0.86 NPSR1 (1.00) SDHBNPSR1LMNASMN1; SMN2STAT3
SCHEMBL19805683 0.85 SDHB (0.71) SDHBNPSR1LMNASMN1; SMN2STAT3
SCHEMBL29977030 0.85 SDHB (0.71) SDHBNPSR1LMNASMN1; SMN2STAT3
SCHEMBL19805679 0.85 SDHB (0.71) SDHBNPSR1LMNASMN1; SMN2STAT3
SCHEMBL19805686 0.85 SDHB (0.73) SDHBNPSR1LMNASMN1; SMN2STAT3
SCHEMBL5785867 0.84 PTGS2 (1.00) SDHBNPSR1LMNASMN1; SMN2STAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1493735-B1 PYRIMIDINE DERIVATIVES USEFUL AS SELECTIVE COX-2 INHIBITORS GLAXO GROUP LTD (GB) 2008-10-29 EP disclosed
US-20070270428-A1 Use of Cyclooxygenase-2 Inhibitors for the Treatment of Depressive Disorders GLAXO GROUP LIMITED (GB) 2007-11-22 US disclosed
US-20060194824-A1 Compositions containing pyrimidine derivatives as inhibitors of cox-2 GLAXO GROUP LIMITED (GB) 2006-08-31 US disclosed
EP-1687001-A2 USE OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIC DISORDERS GLAXO GROUP LIMITED (GB) 2006-08-09 EP disclosed
EP-1687000-A2 USE OF CYCLOOXYGENASE-2 INHIBITORS FOR THE TREATMENT OF DEPRESSIVE DISORDERS GLAXO GROUP LIMITED (GB) 2006-08-09 EP disclosed
US-7084148-B2 Substituted pyrimidines as selective cyclooxygenase-2 inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2006-08-01 US disclosed
CN-1255387-C Pyrimidine derivatives useful as selective COX-2 inhibitors GLAXO GROUP LTD (GB) 2006-05-10 CN disclosed
EP-1390351-B1 PYRIMIDINE DERIVATIVES USEFUL AS SELECTIVE COX-2 INHIBITORS GLAXO GROUP LTD (GB) 2006-05-03 EP disclosed
EP-1254119-B1 PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2 GLAXO GROUP LTD (GB) 2006-04-12 EP disclosed
US-7026327-B2 Pyrimidine derivatives useful as selective COX-2 inhibitors GLAXO GROUP LIMITED (GB) 2006-04-11 US disclosed
EP-1390351-A1 PYRIMIDINE DERIVATIVES USEFUL AS SELECTIVE COX-2 INHIBITORS GLAXO GROUP LIMITED (GB) 2004-02-25 EP disclosed
US-20030109538-A1 Pyrmidine derivatives as selective inhibitors of cox-2 SMITHKLINE BEECHAM CORPORATION 2003-06-12 US disclosed
EP-1313728-A1 SUBSTITUTED PYRIMIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS GLAXO GROUP LIMITED (GB) 2003-05-28 EP disclosed
CN-1399633-A Pyrimidine derivatives GLAXO GROUP LTD (GB) 2003-02-26 CN disclosed
WO-2002096885-A1 PYRIMIDINE DERIVATIVES USEFUL AS SELECTIVE COX-2 INHIBITORS GLAXO GROUP LIMITED (GB) 2002-12-05 WO disclosed
EP-1254119-A1 PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2 GLAXO GROUP LIMITED (GB) 2002-11-06 EP disclosed
EP-1235812-A2 PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2 GLAXO GROUP LIMITED (GB) 2002-09-04 EP disclosed
WO-2002018374-A1 SUBSTITUTED PYRIMIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS GLAXO GROUP LIMITED (GB) 2002-03-07 WO disclosed
WO-2001058881-A1 PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2 GLAXO GROUP LIMITED (GB) 2001-08-16 WO disclosed
WO-2001038311-A2 PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITORS OF COX-2 GLAXO GROUP LIMITED (GB) 2001-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270428-A1 Use of Cyclooxygenase-2 Inhibitors for the Treatment of Depressive Disorders TPH2, PTGS2, PTGES2 SDHB 55/4885NPSR1 142/4885LMNA 4000/4885
US-20060194824-A1 Compositions containing pyrimidine derivatives as inhibitors of cox-2 DPYD, PTGS2, TYMP SDHB 187/4885NPSR1 2616/4885LMNA 4481/4885
US-20030109538-A1 Pyrmidine derivatives as selective inhibitors of cox-2 PTGS1, PTGS2, PTGES2 SDHB 203/4885NPSR1 552/4885LMNA 4389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.